CORAL GABLES, Fla., April 21, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that Steven R. Miller, Ph.D., Catalyst's Chief Operating Officer and Chief Scientific Officer, will be making a presentation on Friday, April 29, 2011 at 2:55pm ET at the Antiepileptic Drug Trials XI Conference, an in-depth, three day forum to be held April 27-29, 2011 at the Turnberry Isle Resort, Aventura (North Miami Beach), Florida. The conference will focus on issues related to antiepileptic drug (AED) development from preclinical discoveries through clinical evaluations. It will bring together representatives from academia, industry, the NIH, and the FDA to review what has been learned and to discuss strategies to enhance AED development.
Dr. Miller will present an overview and the development status of CPP-115, Catalyst's development stage anticonvulsant compound, as a potential treatment for a variety of epileptic conditions, including complex partial seizures and infantile spasms. Further, the Company reported that its presentation materials from the conference will be posted on April 29, 2011 on the Company's website, , under "Events and Presentations."
About Catalyst Pharmaceutical Partners, Inc.
Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting addiction and diseases of the central nervous system. Catalyst has two products in development, and is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109 (vigabatrin), for the treatment of cocaine addiction. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions. Catalyst is also developing CPP-115, another GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including drug addiction, epilepsy and for use in the reduction or elimination of addictive liability in the treatment of pain. CPP-115 has been granted orphan-drug designation for the treatment of infantile spasms by the FDA. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to the inhibition of GABA aminotransferase. For more information about Catalyst, go to .
CONTACT: Patrick J. McEnany, Catalyst Pharmaceutical Chief Executive Officer (305) 529-2522 email@example.com Melody Carey, Rx Communications Group Co-President (917) 322-2571 firstname.lastname@example.org